Pyxis oncology stock prediction.

Fundamentals There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Latest 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or …

Pyxis oncology stock prediction. Things To Know About Pyxis oncology stock prediction.

Description. Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by ... Pyxis Oncology Market Cap: 67.14M, Enterprise value: N/A, P/E: -1.1, PEG ratio: -0.01, EPS: -0.78, Revenue: N/A, EBITDA: -101.49M, Income: -33.59M, ...As of May 10, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 38,245,287. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on ...Real time Pyxis Oncology (PYXS) stock price quote, stock graph, news & analysis.Pyxis Oncology Stock Performance. NASDAQ PYXS opened at $1.63 on Monday. The firm has a 50-day moving average of $1.71 and a 200-day moving average of $2.29. The stock has a market cap of $72.24 ...

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver ...12 brokers have issued 12-month price objectives for Rain Oncology's stock. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,431.5% from the stock's current price.

Description. Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by ...Pyxis Oncology Inc. Real-Time Quotes. 1.44. BATS BZX Real-Time Price. As of Nov 21. 0.00 / 0.00%. Today’s Change. 1.10. Today ||| 52-Week Range.

A high-level overview of Pyxis Oncology, Inc. (PYXS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Pyxis Oncology (PYXS – Research Report).The company’s shares opened today at $2.40. Slutsky covers the ...Earnings for Pyxis Oncology are expected to grow in the coming year, from ($2.01) to ($1.57) per share. Pyxis Oncology has not formally confirmed its next …Comparatively, Pyxis Oncology has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Summary Pyxis Oncology beats Aclaris Therapeutics on 10 of the 17 factors compared between the two stocks.Pyxis Tankers Inc Stock Forecast, Predictions & Price Target. Add to Watchlist. Overview Forecast. Earnings Dividend Ownership. ... Pyxis Tankers Stock Forecast FAQ. What is PXS's forecast return on equity (ROE) for 2023-2023? (NASDAQ: PXS) forecast ROE is 6.23%, which is considered weak.

PYXS - Pyxis Oncology Inc Stock - Stock Price, Institutional Ownership, Shareholders (NASDAQ) ... Forecast. Institutional Owners, 86 total, 85 long only, 1 short ...

Mar 28, 2023 · Pyxis Oncology Inc ( PYXS) has risen Tuesday morning, with the stock increasing 2.59% in pre-market trading to 2.77. PYXS's short-term technical score of 59 indicates that the stock has traded more bullishly over the last month than 59% of stocks on the market. In the Biotechnology industry, which ranks 104 out of 146 industries, the stock ...

Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500. ... to Get Acquired by Pyxis Oncology, Stock Up 05/25/23-2 ... Pyxis Oncology, Inc. is a multi-asset, multi-modality company focused on defeating difficult to treat cancers and improve patient lives. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics.Pyxis Oncology Inc ( PYXS) is up 1.67% today. PYXS has an Overall Score of 85. Find out what this means to you and get the rest of the rankings on PYXS! PYXS stock closed at $6.00 and is up $0.10 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard ...On average, Wall Street analysts predict. that Pyxis Oncology's share price could reach $8.67 by Nov 30, 2024. The average Pyxis Oncology stock price prediction forecasts a potential upside of 445.09% from the current PYXS share price of $1.59. Buy. Initiates. $19. +809.09%. Nov 2, 2021. A list of analyst ratings for Pyxis Oncology (PYXS) stock. See upgrades, downgrades, price targets and more from top Wall Street stock analysts.Description. Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by ...

The value each PYXS share was expected to gain vs. the value that each PYXS share actually gained. Pyxis Oncology ( PYXS) reported Q3 2023 earnings per share (EPS) of -$0.56, missing estimates of -$0.51 by 10.02%. In the same quarter last year, Pyxis Oncology 's earnings per share (EPS) was -$0.85. Pyxis Oncology is expected to release next ... Full-Year 2022 Financial Results. As of December 31, 2022, Pyxis Oncology had cash and cash equivalents (including restricted cash) of $180.7 million, which is expected to fund operations into the ...Pyxis Oncology Inc (PYXS) stock is higher by 8.35% while the S&P 500 has fallen -0.1% as of 11:49 AM on Monday, Apr 3. PYXS is higher by $0.33 from the previous closing price of $4.01 on volume of 6,295,868 shares. Over the past year the S&P 500 is down -10.42% while PYXS is higher by 21.17%. PYXS lost -$3.65 per share the over the …Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer 2023-11-07T16:30:37 Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate UpdatePyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 …Pyxis Announces Pricing of Upsized Initial Public Offering. (GlobeNewswire) Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly ...The Pyxis Oncology, Inc. stock price fell by -2.72% on the last day (Friday, 17th Nov 2023) from $1.47 to $1.43. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 3.50% from a day low at $1.43 to a day high of $1.48. The price has fallen in 8 of the last 10 days and is down by -18.75% for this period.

Recent developments: Pyxis Oncology had acquired Apexigen in a $16M all-stock deal, granting Pyxis access to Apexigen's potential cancer treatments. After the acquisition, Apexigen had become a ...As of June 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 39,376,941. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical-stage company focused on ...

Pyxis Oncology Inc ( PYXS) has risen Tuesday morning, with the stock increasing 2.59% in pre-market trading to 2.77. PYXS's short-term technical score of 59 indicates that the stock has traded more bullishly over the last month than 59% of stocks on the market. In the Biotechnology industry, which ranks 104 out of 146 industries, the stock ...Pyxis Oncology, Inc. (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.7 พ.ย. 2566 ... As of September 30, 2023, the outstanding number of shares of common stock of Pyxis Oncology was 44,294,092. ... predict all risk factors, nor ...On average, Wall Street analysts predict. that Pyxis Oncology's share price could reach $8.67 by Nov 30, 2024. The average Pyxis Oncology stock price prediction forecasts a potential upside of 445.09% from the current PYXS share price of $1.59.Pyxis Oncology issued approximately 4.3 million shares of common stock as a result of this transaction, and immediately post-acquisition, Pyxis Oncology is expected to have 43,872,248 shares of ...Pyxis Oncology Inc ( PYXS) has gained Monday morning, with the stock rising 10.41% in pre-market trading to 2.44. PYXS's short-term technical score of 83 indicates that the stock has traded more bullishly over the last month than 83% of stocks on the market. In the Biotechnology industry, which ranks 106 out of 146 industries, Pyxis Oncology ...Pyxis Oncology didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory ...Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next-generation therapeutics that hold the potential for mono ...

Apexigen surges ~40% on all-stock acquisition by Pyxis Oncology SA News Wed, May 24. Pyxis Oncology GAAP EPS of -$0.54 beats by $0.39 SA News Thu, May 11.

May 24, 2023 · Under the terms of the definitive merger agreement, Pyxis Oncology expects to issue approximately 4.4 million shares of its common stock to Apexigen stockholders to acquire Apexigen. For each ...

Net loss for the three months ended June 30, 2022 and 2021 included $4.0 million and $0.6 million, respectively, related to non-cash stock-based compensation expense. As of August 15, 2022, the ...Pyxis Oncology is devoted to transforming the lives of patients with cancer by advancing our innovative and differentiated portfolio of clinical assets that specifically target tumor cells and overcome immune suppression. We believe that antibody-drug conjugates (ADCs) and immunotherapies offer unique potential to address difficult-to-treat ...Pyxis Oncology Stock Forecast. Is Pyxis Oncology Stock Undervalued? The current Pyxis Oncology [ PYXS] share price is $1.45. The Score for PYXS is 8, which is 84% below its historic median score of 50, and infers higher risk than normal. PYXS is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 1,431.5% from the stock's current price. View analysts price targets for RAIN or view top-rated stocks among Wall Street analysts.News releases. Year. 2023. Nov 28, 2023. Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer. Nov 07, 2023. Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update. Sep 27, 2023.APX801 is an NK cell engager designed to specifically activate natural killer cells leading to effective killing of tumor cells currently at the pre-clinical stage. APX801 was obtained as part of Pyxis Oncology’s acquisition of Apexigen in August 2023 and its development was previously paused by Apexigen. Pyxis, a multiplatform company, is ...This is Pyxis Oncology, Inc.'s initial public offering. We are selling 9,500,000 shares of our common stock. We expect the public offering price to be between ...This is Pyxis Oncology, Inc.'s initial public offering. We are selling 9,500,000 shares of our common stock. We expect the public offering price to be between ...

Nov 30, 2023 · High Growth Earnings: PYXS is forecast to remain unprofitable over the next 3 years. Revenue vs Market: PYXS's revenue (66.6% per year) is forecast to grow faster than the US market (8.1% per year). High Growth Revenue: PYXS's revenue (66.6% per year) is forecast to grow faster than 20% per year. Pyxis Oncology, Inc. (PYXS) Stock Price, Quote & News - Stock Analysis 1.55 +0.15 (10.71%) At close: Nov 24, 2023, 1:00 PM 1.43 -0.12 (-7.74%) After-hours: …Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500. ... to Get Acquired by Pyxis Oncology, Stock Up 05/25/23-2 ... Instagram:https://instagram. spac stock price1 month treasury rateetf for restaurantsiso2022 coins Pyxis Oncology ( NASDAQ: PYXS) is a biotech based in Cambridge, Massachusetts, with two therapeutics in the clinic that have potential in various cancer types. The stock reached a recent low in ...Pyxis Oncology, Inc. Common Stock. P/E & PEG Ratios. call and put options information of stocks. Financial analysts and individual investors can rely on the chain to gauge the stock's performance ... themoneyistday trading courses free Fundamentals There is no chart data available for this period 1d 1w 1m 3m 6m 1y All Latest 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here or …Pyxis Oncology Inc (PYXS) stock is up 9.87% while the S&P 500 is lower by -0.69% as of 2:04 PM on Friday, May 12. PYXS has risen $0.30 from the previous closing price of $3.04 on volume of 1,647,588 shares. Over the past year the S&P 500 has risen 4.24% while PYXS has risen 57.55%. PYXS lost -$3.65 per share in the over the last 12 … ebnd PYXS Earnings Date and Information. Pyxis Oncology last announced its earnings results on November 7th, 2023. The reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01. Pyxis Oncology has generated ($2.55) earnings per share over the last year ( ($2.55) diluted earnings per share).Practice. In this article, we shall build a Stock Price Prediction project using TensorFlow. Stock Market price analysis is a Timeseries approach and can be performed using a Recurrent Neural Network. To implement this we shall Tensorflow. Tensorflow is an open-source Python framework, famously known for its Deep Learning and Machine …Dec 1, 2023 · According to analysts, Pyxis Oncology's stock has a predicted upside of 311.52% based on their 12-month stock forecasts. What analysts cover Pyxis Oncology? Pyxis Oncology has been rated by HC Wainwright , Royal Bank of Canada , and William Blair in the past 90 days.